In collaboration with the National Institute of Allergy and Infectious Diseases and the Center for Disease Control and Prevention, NCI has developed COVID-19 Seroprevalence Hub (COVID-19 SeroHub), a central repository of SARS-CoV-2 seroprevalence studies. These studies use blood tests to identify the proportion of people in the population who possess antibodies to SARS-CoV-2 as an indication of prior infection. Seroprevalence data shows how the virus is spreading within the U.S. population, enabling scientists and policymakers to better understand who is most at risk for disease, as well as who might be protected from infection.

Using COVID-19 SeroHub, researchers can track studies conducted by various contributors at the national, state, and local levels on the seroprevalence of SARS-Cov-2 throughout the United States. An interactive dashboard allows scientists to visualize and compare SARS-Cov-2 seroprevalence rates by geography, dates of testing, and population descriptors.

Learn more about COVID-19 SeroHub and how researchers and policymakers can use it to monitor the spread of COVID-19 across the country since the beginning of the pandemic to facilitate evidence-based decision making, inform future studies, and identify scientific gaps and disparities.